(Q43662390)

25 November 2017

title

Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial (English)

1 reference

25 November 2017

0 references

1 reference

D S Robinson

1

1 reference

25 November 2017

D Campbell

series ordinal

2

1 reference

25 November 2017

P J Barnes

series ordinal

3

1 reference

25 November 2017

language of work or name

English

0 references

publication date

1 June 2001

1 reference

25 November 2017

1 reference

25 November 2017

volume

357

1 reference

25 November 2017

issue

9273

1 reference

25 November 2017

page(s)

2007-2011

1 reference

Treatment of asthma with drugs modifying the leukotriene pathway.

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905113-8

7 January 2021

Leukotriene modifiers in the treatment of asthma. Look promising across the board of asthma severity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905113-8

7 January 2021

Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905113-8

7 January 2021

Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905113-8

7 January 2021

Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905113-8

7 January 2021

Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905113-8

7 January 2021

A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905113-8

7 January 2021

Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905113-8

7 January 2021

Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905113-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905113-8

1 reference

7 January 2021

Difficult-to-control asthma: clinical characteristics of steroid-insensitive asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905113-8

7 January 2021

Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905113-8

7 January 2021

An evaluation of zafirlukast in the treatment of asthma with exploratory subset analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905113-8

7 January 2021

Effect of oral prednisone on airway inflammatory mediators in atopic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905113-8

7 January 2021

Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905113-8

7 January 2021

The Pivotal Role of 5-Lipoxygenase Products in the Reaction of Aspirin-sensitive Asthmatics to Aspirin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905113-8

7 January 2021

Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905113-8

7 January 2021

Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905113-8

7 January 2021

Inhaled corticosteroids versus anti-leukotrienes: a literature review on the clinical effects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2800%2905113-8

7 January 2021

10.1016/S0140-6736(00)05113-8

Identifiers

DOI

1 reference

25 November 2017

1 reference